Member Info for CW25

L2 is lighting up again!

@info hope its tomorrow and not another friday RNS!

At the moment i just think this is MM's playing with the SP to create a market. When i rises sharply a lot of buys come in hence the volume. Then they drip it down slowly to release the shares from weak hands and since and repeat. I dont believe there is any leak, especially as no new news after the last rise a few weeks ago. Looks like traders are back on the share, maybe it is the Amigo crew after all.

Did the same last year in June before the AGM. Quite happy for RM to have some More shares! Also good to see Richard jennings had some options.

I agree, but any deal may also be based on the SP at any one point. For example a JV could involve shares at a certain price and cash. They may well have instructed the MM’s to lift the price. Shouldn’t be allowed but happened before when we went from 85p to 180 in a short space of time.

Leaf,
To be fair I had the same thoughts and made a joke out of it the other day when it was rising! It had the same characteristics as the last placing in SP movement. Do I honestly think they need to fund more? no, well not for now. And that’s where the uncertainty lies. Yes we will need more cash if we are to stock the drug to sell and start the full manufacturing process. However they can only really tap up investors for cash if it is 1. An approved drug. 2. Pre-orders. 3. Or Activ2 needs to see we have the cash to manufacture (if we decide to go it alone). Yes the US gov would be helping but how much we don’t know.
All I know is if there is another placing It can only really come with a pre order or post p3 approval. Until then they have enough cash to get the trials done. In which case we’re laughing anyway and I certainly wouldn’t want to be out of half my stake at that point.
So yes it’s a good thing to question a placing and also the fact that we may not progress to p3 on Activ2, but I don’t agree it was right to take some off the table at this point.

A nice £325k buy on the bell today. Maybe someone had serious fomo or maybe they have some news! We’ll see Monday. Good weekend all

I think based on our UK p2 home trial it would be a surprise if we were passed on to p3 in US. If it shows similar results I can’t see that being enough for the US to find it further. Our data is all about the numbers and the more patients dosed gives us more chance of success or to put it better more exacerbated patients the better results. It’s a bonus for me if Activ2 progresses. All eyes on p3 hospital trial for the rerate.

I smell a placing!! Haha only joking! We are fully funded and ready to take the world on.
Oh fcuk it - I’m all in again! GLA

or is it org?! lol

Right here too all the way till the end! Just took a step back whilst i licked my wounds! x

Another leak last Friday then! Getting predicable with our day before rises before an rns.

Anyway great progress and reminds everyone in layman’s terms what our drug is about. Agree this will put a bottom on the current SP. Nice to also see they are doing other things behind the Scenes we don’t know about.

Not sure the last 5 bagger came out of nowhere. We were very much awaiting (impatiently may i add) p2 results!!

Good to hear. I’m also waiting with cash ready to pounce on any drops. Slightly less stressful not being all in but at the same time feel like I’m cheating on the company. My belief hasn’t changed but timeframes have slipped. I will be fully reloaded by the end of p3.

@woody you ok mate?

Gilead global commercial director - respiratory.
Commercial Head responsible for commercial assessments & BD/ R&D collaborations leading to portfolio expansion.
In-house development programs - COPD, Cystic Fibrosis (CF), Bronchiectasis, RSV, Idiopathic Pulmonary Fibrosis (IPF)
Acquisition/ Licensing - Arresto (IPF), MicroDose (RSV).
Also responsible for CAYSTON (inhaled antibiotic treatment for CF) global commercial launch.

This guy knows his stuff. Huge appointment from RM. and he knows ALL the right people!

What a prat.

Teamwork - nope still in. However, reduced my position by 50% on Friday at 1.48p as i didn't like how the market might perceive the p2 news. I have waited since manic Monday to cash some out (other than small bits for my house) and thought, like others that the p2 would see a boost to the SP. Whilst the p2 didn't show anything alarming to dampen my enthusiasm it was somewhat underwhelming due to most of the patients having low exacerbations (my parents including). I truly believe the p3 will give us great results and a route to market but based on the home trial data i am unsure whether the Activ2 trial will show enough efficacy to proceed to p3. That being the case the SP would take another hit. If it goes the other way and is successful then i still have 50% (100k shares) invested. I am using funds to buy back in on the dips (i bought some more this morning) and will continue to do so until i am pretty much fully back in before the p3 news drops. However until we get the last patient dosed RNS I will use the opportunity to invest elsewhere in recovery stocks as the UK opens back up.
So yes i have reduced but i has no less belief, more infact, that the p3 hospital trial will be good. Whether covid is still here is another debate but there will still be significant uplift to the SP for a fully approved anti viral virus agnostic drug for the future, if not now. Just playing the long game now and not being 'all in' for a while again which wasn't healthy on the heart!

no reassurance on my part needed but thanks for the concern. No need for anyone to panic either. If this was bad news it would have dropped 50%+ not 10%.

July 2020 RNS - "Positive results from trial in COVID-19 patients"
Today "Home Cohort data of SG016 Phase II trial"
Says it all.